Tuesday, November 17, 2026

Lotte Biologics Wins First Commercial Production Contract for Songdo Plant 1, Securing Production Volume Before Operations Begin

Input
2026-11-17 10:54:00
Updated
2026-11-17 10:54:00
[Financial News] Lotte Biologics has won its first large-scale commercial production contract for Plant 1 at its Songdo Bio Campus in Incheon. With a global pharmaceutical company secured as a customer ahead of the plant’s full-scale launch in 2027, the company has secured production volumes from the early stages of operations. The deal is seen as an important turning point in the company’s business expansion, as Lotte Biologics, a late entrant to the global contract development and manufacturing organization (CDMO) market, has secured commercial production volumes before completing its production facility.
Lotte Biologics said on the 17th that it had signed a contract with a global pharmaceutical company to manufacture biopharmaceuticals on a contract manufacturing (CMO) basis. Under the agreement, Lotte Biologics will handle the entire process for key customer products, from producing clinical-stage drug substances to producing commercial drug substances and finished drug products. The company did not disclose details such as the contract value, the customer’s name or product information.
The contract is significant because Lotte Biologics secured a customer while Songdo Plant 1 was still under construction. Biopharmaceutical production facilities typically begin actively attracting customers and securing production volumes after construction is complete. By signing a commercial production contract before the plant begins operations, Lotte Biologics has laid the groundwork for a higher initial utilization rate.
Songdo Plant 1, which will produce the contracted volumes, has a total capacity of 120,000 liters. It is equipped with eight 15,000-liter stainless steel bioreactors and is targeting full-scale commercial production in 2027.
Lotte Biologics is building a dual-site production system linking its Syracuse Bio Campus in the State of New York, United States, with its Songdo production facility. The Syracuse campus has a track record in commercial production, and the company plans to apply in Songdo the regulatory engagement and quality management experience it has accumulated there. The Syracuse campus has received at least 62 regulatory approvals to date and recently passed an inspection by the U.S. Food and Drug Administration (FDA) with no observations.
The contract is also drawing attention as the first result that offers a measure of the commercial value of the Songdo production facility. With a new facility equipped for large-scale production now securing actual customer volumes, additional contracts and facility utilization are expected to be key factors in the company’s future growth.
“Building on the quality strengths we have developed and our stable supply capabilities, we will support the commercialization of our customers’ new drugs,” said James Park, CEO of Lotte Biologics.

[email protected] Jung Sang-hee Reporter